γδ T cells in autoimmune uveitis pathogenesis: A promising therapeutic target

Biochem Pharmacol. 2023 Jul:213:115629. doi: 10.1016/j.bcp.2023.115629. Epub 2023 May 29.

Abstract

Autoimmune uveitis is a non-infectious, inflammatory intraocular disease that affects the uveal and adjacent tissues. It frequently causes varying degrees of visual loss. Evidence for the strong association between activated γδ T cells and the development of autoimmune uveitis is growing. The innate and adaptive immune response are connected in the early phases by the γδ T cells that contain the γ and δ chains. γδ T cells can identify antigens in a manner that is not constrained by the MHC. When activated by various pathways, γδ T cells can not only secrete pro-inflammatory factors early on (such as IL-17), but they can also promote Th17 cells responses, which ultimately exacerbates autoimmune uveitis. Therefore, we review the mechanisms by which γδ T cells affect autoimmune uveitis in different activation and disease states. Moreover, we also prospect for immunotherapies targeting different γδ T cell-related action pathways, providing a reference for exploring new drug for the treatment of autoimmune uveitis.

Keywords: Autoimmune uveitis; Dendritic cells; Experimental autoimmune uveitis; Th17 cells; γδ T cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoimmune Diseases* / drug therapy
  • Autoimmune Diseases* / immunology
  • Humans
  • Immunotherapy* / methods
  • Interleukin-17 / metabolism
  • Intraepithelial Lymphocytes* / drug effects
  • Intraepithelial Lymphocytes* / immunology
  • Lymphocyte Activation*
  • Th17 Cells / immunology
  • Uveitis* / drug therapy
  • Uveitis* / immunology

Substances

  • Interleukin-17